No one can deny that the hype of CBD is alluring. Is CBD a magical cure-all? Are the claims about the non-psychoactive extract from cannabis substantiated?

We did some research and found that while not all CBD is created equal, the research has shown surprising evidence of the efficacy of CBD in treating certain types of childhood epilepsy that don’t responded to normal anti-siezure meds, marijuana induced psychosis, skizophrenia, anxiety, neuropathic pain, and inflammatory diseases. CBD has even been shown to make cancer treatment more effective in prostate cancer, hepatocellular carcinoma, and breast adenocarcinoma. Moreover, there is no denying that CBD is a powerful antioxidant, resulting in it’s neuroprotective properties through reducing oxidative stress. Research shows this as a potential for treating alzheimers disease. Finally, there have been reports that CBD causes neurogenisis, or neural growth, in the hippocampus (center of memory, learning, and emotion) and the lateral ventricles (where the fluid that provides cushion, helps nutrients circulate, and removes waste is located). This points to CBD being a potential nootropic.

CBD makes it’s effects through the endocannabinoid system. There are two types of cannabinoid receptors, the CB1 and CB2 receptors. As far as how the parts of marijuana interact with these receptors, the CB1 receptor is mostly influenced by THC and the CB2 receptors is mostly influenced by CBD. Interestingly, the effects that THC or CBD have are dependent on not only which receptors these active ingredients (THC and CBD) act, but where the receptors are located. This accounts for the fact that THC can cause relaxation in lower doses and anxiety in higher doses. CBD can also have a weak negative effect on the CB1 receptors (in some areas of the brain) that THC activates, and this can account for it’s effectiveness in counteracting that anxiety at higher doses. It makes sense then that CBD has also been shown to be very effective in treating marijuana-induced psychosis. Strains of marijuana that have a higher ratio of CBD to THC have been shown to cause less psychosis in general.

Moreover, CBD is partially activating to receptors that some popular antipsychotic medications are (D2 and 5-HT1), accounting for it’s efficacy in abating anxiety and psychotic symptoms in skizophrenia. Also, the CB2 receptor (which CBD mostly acts on) is associated with the immune system, which could account for CBD’s effectiveness in treating inflammation, which by definition is the immune response gone haywire. The questions needs to be asked, though: what about treating patients that do not have enough immune response (such as HIV/AIDS)? What about CBD’s effect on a healthy immune system? Although less clear, some research points to CBD actually strengthening the immune system in those immuno-compromised individuals (HIV/AIDS). There haven’t been reports of a negative impact on the immune systems of healthy individuals, either.

The bottom line is that many body processes are a function of the complex endocannabinoid system, and CBD has been shown to induce harmony through modulation of this system. The problem with the CBD industry currently is that it is unregulated, so the purity of the product isn’t verified. It’s important to have a good supplier if CBD is a nootropic you’d like to add to your stack.

Pin It on Pinterest

Share This